Affordable Access

deepdyve-link
Publisher Website

Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4.

Authors
  • Y, Ren
  • Hw, Cheung
  • G, Von Maltzhan
  • A, Agrawal
  • Gs, Cowley
  • Ba, Weir
  • Js, Boehm
  • P, Tamayo
  • Am, Karst
  • Jf, Liu
  • Ms, Hirsch
  • Jp, Mesirov
  • R, Drapkin
  • De, Root
  • J, Lo
  • Valentina Fogal
  • Erkki Ruoslahti
  • Wc, Hahn
  • Sn, Bhatia
Type
Published Article
Journal
Science Translational Medicine
Publisher
American Association for the Advancement of Science (AAAS)
Volume
4
Issue
147
Identifiers
DOI: 10.1126/scitranslmed.3003778
Source
Ruoslahti Lab
License
Unknown

Abstract

The comprehensive characterization of a large number of cancer genomes will eventually lead to a compendium of genetic alterations in specific cancers. Unfortunately, the number and complexity of identified alterations complicate endeavors to identify biologically relevant mutations critical for tumor maintenance because many of these targets are not amenable to manipulation by small molecules or antibodies. RNA interference provides a direct way to study putative cancer targets; however, specific delivery of therapeutics to the tumor parenchyma remains an intractable problem. We describe a platform for the discovery and initial validation of cancer targets, composed of a systematic effort to identify amplified and essential genes in human cancer cell lines and tumors partnered with a novel modular delivery technology. We developed a tumor-penetrating nanocomplex (TPN) that comprised small interfering RNA (siRNA) complexed with a tandem tumor-penetrating and membrane-translocating peptide, which enabled the specific delivery of siRNA deep into the tumor parenchyma. We used TPN in vivo to evaluate inhibitor of DNA binding 4 (ID4) as a novel oncogene. Treatment of ovarian tumor-bearing mice with ID4-specific TPN suppressed growth of established tumors and significantly improved survival. These observations not only credential ID4 as an oncogene in 32% of high-grade ovarian cancers but also provide a framework for the identification, validation, and understanding of potential therapeutic cancer targets.

Report this publication

Statistics

Seen <100 times